SCHEMBL6450550

SCHEMBL6450550

O=C(NCCNCCO)C(F)(F)F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA3 P07451 2/20 0.73
CA5A P35218 2/20 0.73
CA5B Q9Y2D0 2/20 0.73
CA14 Q9ULX7 2/20 0.61
CA2 P00918 2/20 0.61
CA12 O43570 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
ALDH1A1 P00352 5/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
POLB P06746 1/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
EPHX1 P07099 1/20 0.47
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
MTNR1A P48039 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10231803 0.91 CA3 (0.86) CA3CA5ACA5BCA14CA2
SCHEMBL1252712 0.91 CA3 (0.86) CA3CA5ACA5BCA14CA2
SCHEMBL733643 0.86 ALDH1A1 (0.68) CA3CA5ACA5BCA14CA2
SCHEMBL13861685 0.83 ALDH1A1 (0.79) CA3CA5ACA5BCA14CA2
SCHEMBL20067631 0.81 CA3 (0.59) CA3CA5ACA5BCA14CA2
SCHEMBL8041559 0.81 CA5B (0.77) CA3CA5ACA5BCA14CA2
SCHEMBL10232648 0.81 CA5B (0.77) CA3CA5ACA5BCA14CA2
SCHEMBL467536 0.78 CA3 (0.67) CA3CA5ACA5BCA14CA2
SCHEMBL865618 0.77 ALDH1A1 (0.77) CA3CA5ACA5BCA14CA2
SCHEMBL3142216 0.77 CA3 (0.95) CA3CA5ACA5BCA14CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117051-A1 MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技有限责任公司 2022-06-09 WO disclosed
WO-2022117051-A1 MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技有限责任公司 2022-06-09 WO disclosed
CN-114057771-A Macrocyclic compound and preparation method and application thereof 北京鞍石生物科技有限责任公司 2022-02-18 CN disclosed
EP-1126838-A4 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-02-16 EP disclosed
US-20030207919-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NICOX S.A. (FR) 2003-11-06 US disclosed
US-6593347-B2 Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam NITROMED, INC. 2003-07-15 US disclosed
US-20020016322-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use NICOX S.A. (FR) 2002-02-07 US disclosed
US-6297260-B1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NITROMED, INC. 2001-10-02 US disclosed
EP-1126838-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-08-29 EP disclosed
WO-2000025776-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016322-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use NOS2, NOS3, NOS1 CA3 1043/4885CA5A 532/4885CA5B 321/4885
US-20030207919-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NOS2, NOS1, NOS3 CA3 2908/4885CA5A 559/4885CA5B 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.